Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab

Código QR

Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab

Guardado en:

Detalles Bibliográficos
Autores principales:	Tian Zhang, Brian I. Rini, Moshe C. Ornstein, Daniel J. George, Chester Kao, Landon C. Brown, Kunal Desai, Emily N. Kinsey
Formato:	article
Lenguaje:	EN
Publicado:	BMJ Publishing Group 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/f2f0d499ad64464c9004ed84c9fdb464
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma
por: Matthew D. Tucker, et al.
Publicado: (2021)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Alexander N Shoushtari, et al.
Publicado: (2021)

Ipilimumab and Nivolumab induced ventricular tachycardia in a patient with metastatic renal cell carcinoma
por: Pramod Savarapu, et al.
Publicado: (2021)

Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab
por: Koji Iinuma, et al.
Publicado: (2021)

Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data Study
por: Morten Fink, et al.
Publicado: (2021)

Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab
por: Toshiki Kijima, et al.
Publicado: (2021)

A Case of Vogt-Koyanagi-Harada Disease-Like Uveitis Induced by Nivolumab and Ipilimumab Combination Therapy
por: Keisuke Minami, et al.
Publicado: (2021)

Correction: Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab
Publicado: (2021)

Novel Prognostic Score for recurrent or metastatic head and neck cancer patients treated with Nivolumab
por: Kiyoshi Minohara, et al.
Publicado: (2021)

Treatment-free survival after discontinuation of immune checkpoint inhibitors in metastatic renal cell carcinoma: a systematic review and meta-analysis
por: Alice Tzeng, et al.
Publicado: (2021)

IgA Nephropathy Secondary to Ipilimumab Use
por: Sean C. Dougherty, et al.
Publicado: (2021)

Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)
por: Shahneen Sandhu, et al.
Publicado: (2021)

Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy
por: Ye Peng, et al.
Publicado: (2021)

Complete regression of metastatic malignant melanoma endoscopically after nivolumab administration
por: Dae Gon Ryu, et al.
Publicado: (2021)

Autoimmune hemolytic anemia during long‐term administration of nivolumab for metastatic melanoma
por: Koji Nakajima, et al.
Publicado: (2021)

Use of ipilimumab in the treatment of melanoma
por: Acharya UH, et al.
Publicado: (2013)

Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab
por: William L Redmond, et al.
Publicado: (2021)

Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study
por: Romualdo Barroso-Sousa, et al.
Publicado: (2021)

Phase II Study of Nivolumab Plus Ipilimumab with Platinum-Based Chemotherapy for Treatment-Naïve Advanced Non-Small Cell Lung Cancer with Untreated Brain Metastases: NIke Trial (LOGiK2004)
por: Tsuchiya-Kawano Y, et al.
Publicado: (2021)

An Open–Label, Randomized, Multi–Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin–2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma
por: Merve Hasanov, et al.
Publicado: (2021)

Effect of antibiotic use on the efficacy of nivolumab in the treatment of advanced/metastatic non-small cell lung cancer: A meta-analysis
por: Huo Geng-wei, et al.
Publicado: (2021)

Nivolumab-Induced Exocrine Pancreatic Insufficiency
por: Boudewijn Sweep, et al.
Publicado: (2021)

Nivolumab-induced new-onset seronegative rheumatoid arthritis in a patient with advanced metastatic melanoma: A case report and literature review
por: Ammar Haikal, et al.
Publicado: (2018)

MET Amplification and Efficacy of Nivolumab in Patients With NSCLC
por: Katsuhiro Yoshimura, MD, PhD, et al.
Publicado: (2021)

Use of nivolumab for colon cancer with Lynch syndrome
por: G. A. Khakimov, et al.
Publicado: (2020)

Metastatic myxoid liposarcoma to the tongue: a unique intraoral metastasis
por: Dimitris Tatsis, et al.
Publicado: (2020)

Nivolumab-associated DRESS in a genetic susceptible individual
por: Qian Li, et al.
Publicado: (2021)

IL-10 Signaling Elicited by Nivolumab-Induced Activation of the MAP Kinase Pathway Does Not Fully Contribute to Nivolumab-Modulated Heterogeneous T Cell Responses
por: Taylor A. Harper, et al.
Publicado: (2021)

Treating Metastatic Brain Cancers With Stem Cells
por: Nadia Sadanandan, et al.
Publicado: (2021)

Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab
por: Rosaria De Filippi, et al.
Publicado: (2021)

Determinants of renal cell carcinoma invasion and metastatic competence
por: Kangsan Kim, et al.
Publicado: (2021)

Combination of gene set signatures correlates with response to nivolumab in platinum-resistant ovarian cancer
por: Ryusuke Murakami, et al.
Publicado: (2021)

Immune oncology (IO) and metastatic lung cancer [CBD]: Curability, bony metastasis and duration of therapy
por: Hunter C Cochran, et al.
Publicado: (2021)

An unexpected N-terminal loop in PD-1 dominates binding by nivolumab
por: Shuguang Tan, et al.
Publicado: (2017)

Risk Stratification and Treatment Algorithm of Metastatic Renal Cell Carcinoma
por: Marc-Oliver Grimm, et al.
Publicado: (2021)

Androgen receptor increases hematogenous metastasis yet decreases lymphatic metastasis of renal cell carcinoma
por: Qingbo Huang, et al.
Publicado: (2017)

Kidney injury molecule-1 inhibits metastasis of renal cell carcinoma
por: Jasper C. Lee, et al.
Publicado: (2021)

Sphingomyelin nanosystems loaded with uroguanylin and etoposide for treating metastatic colorectal cancer
por: Belén L. Bouzo, et al.
Publicado: (2021)

Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker for Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Xiuqiong Chen, et al.
Publicado: (2021)

Treating cancer stem cells and cancer metastasis using glucose-coated gold nanoparticles
por: Hu C, et al.
Publicado: (2015)